EGFR and non-small cell lung carcinoma: Regarding the imperfect correlation between EGFR-activating mutations and EGFR-TKI therapy response (e.g., ~20–30% of EGFR-activating mutation-positive NSCLC patients do not respond to EGFR-TKIs), we performed an observational clinical study to evaluate the relationship between HX103-based FACS analysis and response to EGFR-TKI in EGFR-mutant NSCLC patients (Fig. 6a).